Clotiazepam was administrated to the 24 cases of glossodynia.
The following results were obtained:
1) 37.5% of the patients exhibited markedly effective results, 29.2% effective and 33.3% ineffective.
2) 73.7% of the patients improved in anxiety symptom.
3) No serious side effects were observed.
The results indicate the usefulness of clotiazepam on the glossodynia with cancerphobia.

抄録全体を表示

A multi-clinic double blind study was conducted to evaluate the analgesic efficacy and safety of EB-382, in comparison with indomethacin on the postexodontic pain.
1) Total prescription cases were 500. Analized cases were 270. Drop-out and excluded cases were 5 and 7 each. Clinically evaluated cases were 258.
2) EB-382 group was superior to indomethacin group on the ratio of“markedly improved, ”“over moderately improved, ”and“over slightly improved, ”in global improvement rating of a pain.
3) With respect to time till appearance to effect after admistration, EB-382 group was significantly faster than indomethacin group (p<0.01) .
4) Side effects were reported 4 cases in 124 cases of EB-382 group and 6 cases in 139 cases of indomethacin group. The side-effects were almost mild.
5) EB-382 group was superior to indomethacin group on the ratio of“mardedly useful”“over moderately useful” and “over slightly usefu 1” in overall clinical evaluation rating.
Summarizing the above results, it can be concluded that EB-382 is a useful drug for exodontic pain.

抄録全体を表示

Experimental and clinical studies were carried out on latamoxef (LMOX), a synthetic antibiotic of the oxacephem group, with the following results.
1) To test antibacterial activity, MIC was measured for 208 strains of 20 species, isolated clinically and kept in our department, and in the same time MIC of CEZ, CMZ and CPZ also was measured as control drugs. The results indicated that LMOX was far inferior to other drugs against gram-positive bacteria but far superior against gram-negative bacteria.
2) The concentrations in serum and the tissue of the oral cavity were measured by means of bioassay in 21 cases of oral surgery and 1 case of infection with abcess formation after d.i. of LMOX 1g for 1 hour and successive testing of the serum and tissue from the oral cavity. The concentration in the serum showed an average of 57.4μg/ml at the end of drip infusion and 6.0μ/ml 360 minutes after the start. The concentration in the tissue showed a transfer of 20-40% from the serum in the gingiva and mucosa at the end of drip infusion and approximately 10% in the mandibular bone.
3) A clinical study was made in 19 cases of acute oral infection. The rate of effective ness was 79.0%. A slight increase in GOT and GPT was noted as a side effects in 2 cases.
4) The results with regard to anti-bacterial registance to gram-positive bacteria were worse than those for other substances in fundamental studies, but clinically LMOX was effective.
While LMOX is undoubtedly a superior antibiotic, in the oral cavity it is more appropriate for application to intractable secondary infection and relatively serious delayed infections than for primary infections.

抄録全体を表示

In an effort to survey antibiotic preparations actually used in dental practice, a multi-institutional study was made of the consumption and share of antibiotics as classified by chemical structure and dosage form. The study involved 17 private dental colleges or university hospitals in Japan, and consisted of two parts : one, investigation of the share of antibiotic preparations used in a period of 10 days from 6th June through 15th June, 1983, and the other, categorization of antibiotics used over a 9-month period from April through December 1983.
Antibiotic drugs accounted for 23.4% of all oral preparations, and ranked second just behind anti-inflammatory and analgesic drugs which accounted for 27.8%. The order of share in descending frequency was : cephem series including Cephalexin and Cephachlor ; penicillin series such as Amoxycillin, Talampicillin, and Bacampicillin ; and macrolide antibiotics such as Josamycin. Injectable antibiotic preparations were used in as many as 81% of patients who were given injectable forms. The breakdown is as follows : cephem series, 73%; penicillin series, 20%; and others comprising aminoglycosides, lincomycins and tetracyclines, only 7%.
Cephem and penicillin preparations were found to constitute the most commonly used antibiotics in dental practice, with this trend sharing all dental colleges and university hospitals in Japan.

抄録全体を表示

The purpose of this study was to evaluate dentifrices containing sodium chloride and anti-inflammatory agents on the improvement of periodontal disease.
Ninety four subjects which included patients with gingivitis or marginal periodontitis were divided into 3 groups: Group 1, Dentifrice containing 10% sodium chloride and 0.05% tranexamic acid (Dentifrice T₁) ; Group 2, Dentifrice containing 10% sodium chloride, 0.03% ε-amino caproic acid and 0.05% dipostassium glycyrrhizinate (Dentifrice T₂) ; Group 3, Dentifrice containing 9% sodium chloride, 0.03% ε-amino caproic acid and 0.03% aluminium chlorihydroxy allantoinate (Dentifrice T₃) .
Tooth-brushing was performed by all subjects twice a day for four weeks. The clinical observation was performed with respect to redness, swelling, bleeding, pus discharge and pocket depth.
The results were summarized as follows:
1) Dentifrice T₁was significantly superior to dentifrice T₃in the improvement of bleeding (p<0.10) and pus discharge (p<0.01) .
2) Dentifrice T₂ was significantly superior to dentifrice T₃ in the improvement of pus discharge (p<0.01) and pocket depth (p<0.05) .
3) Noparticular side effect was observed through this clinical study.

抄録全体を表示

We use“ACESS”for children, the paste of Satou pharmaceutial Co., Inc., for serious mentally and physically handicapped children and adults having inflammation in gingiva, we observed the progress of every kind of clinical symptom, studied the improvement rate, and judged the effect of this paste.
The results as follows.
1) The efficacy rate of this paste was 92.1% (58 of 63 examples) at the forth week after we began to use this, and the last week 98.1% (62 of 63 examples) .
2) The improvement rate of this paste showed 84.7% on redness, 90.7% on tumor, 88.1% on bleeding, 85.7% on pus discharge, 68.1% on smell of mouth four weeks later.
3) On the efficacy of this paste, the improvement rate of the redness was 68.7% at the second week after we began to use this, the tumor was 92.2% in earlier.
4) The oral smell and the smell of the institution was decreased than before this paste used.
5) There was no special side-effect.
As the result, “ACESS”for children was considered effective tooth paste for the gingivitis of seriously mental and physical handicapped children.

抄録全体を表示

We administered Ketoprofen injectable to 22 cases (19 patients) with pain and 4 cases (4 patients) with fever, treated at the Department of Dentistry and Oral Maxillofacial Surgery, Medical College of Oita, between June 1983 to March 1984. We examined its analgesic and anti-pyretic effect, and obtained the following results.
1) To 22 cases with pain and 4 cases with fever, Ketoprofen injectable 50mg was added up to twice a day in cases with fever and three times in cases with pain.
2) In all cases, the results of improvement were devided into four classes. Then the ratio of remarkable improvement was 34.6% (9/26), the moderate improvement was 50.0% (13/26) and the ratio of both was 84.6%.
3) The ratio of its remarkable usefulness was 26.9% (7/26), the usefulness 53.8% (14/26) and the ratio of both 80.8%.
4) The side effects were observed in two out of 26 cases (7.7%), but these two cases were recorded from one patient with different periods. Therefore, the side effects were observed only in one out of 23 patients (4.3%) .
From above mentioned results we could conclude that the Ketoprofen injectable was an effective and useful non-steroidal analgesic, anti-inflammatory and anti-pyretic agent with big safety in the field of oral and maxillofacial surgery.

抄録全体を表示

Long acting amoxicillin granules (C-AMOX), a newly developed presentation of amoxicillin (AMPC), maintains an effective blood level for an extended period. In order to confirm the utility of C-AMOX, a double-blind comparative study with AMPC capsule was carried out in the treatment of various oral and maxillofacial infections.
A total of 233 cases were participated in the study and 208 cases were evaluated in the efficacy (105 for C-AMOX group and 103 for AMPC group) .
Results obtained were as follows:
1) Clinical efficacy was evaluated according to the criteria of numerical judgement established by the Japanese Society of Oral Surgery (1973) and, in addition, judged by doctor in charge. In the evaluation of numerical judgement, the efficacy rate was 82.0 for C-AMOX group and 80.7% for AMPC group. There was no significant difference between the two groups.
In judgement of clinical efficacy by doctor in charge, the efficacy rate was 81.5% for C-AMOX group and 74.7% for AMPC group. C-AMOX group was superior to AMPC group in the evaluation and difference was significant (p<0.05) .
2) The organisms were isolated from 84 cases (166 strains-aerobic bacteria 72 and anaerobic bacteria 94) out of 90 cases. C-AMOX and AMPC group showed an excellent MIC against both aerobic and anaerobic pathogens. There was no significant difference in the bacteriological efficacy.
3) As for safety evaluation, slight adverse reactions such as diarrhea, nausea, headache and flare of face were observed in 4 cases (3.8%) treated with C-AMOX group and in 4 cases (4.0%) treated with AMPC group. The administration of one case in C-AMOX group was discontinued.
Abnormal laboratory findings were observed in one case with C-AMOX and in 2 cases with AMPC.
There was no significant difference between the two groups.

抄録全体を表示